Durect News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.05.18	DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine) (PR Newswire)
02.05.18	DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update (PR Newswire)
25.04.18	DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (PR Newswire)
24.04.18	DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call (PR Newswire)
04.04.18	Smart Cannabis Signs Collaboration Deal with Dyna-Gro® to Distribute and Test New Advanced Nutrient Solutions (PR Newswire)
29.03.18	DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis (PR Newswire)
20.03.18	DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER (PR Newswire)
01.03.18	DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs (PR Newswire)
26.02.18	DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC) (PR Newswire)
22.02.18	DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call (PR Newswire)
20.02.18	DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC) (PR Newswire)
14.02.18	DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics (PR Newswire)
09.01.18	Regpack Introduces Purchase Protection to the Registration Market (PR Newswire)
13.12.17	DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot (PR Newswire)
01.11.17	DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
26.10.17	DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call (PR Newswire)
19.10.17	DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint (PR Newswire)
04.10.17	ECYT On A Roll, MannKind Delighted, DRRX Gains On Patent Deal, PTCT Slumps (RTTNews)
02.10.17	DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement (PR Newswire)
20.09.17	DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development (PR Newswire)
09.08.17	TEDxSeattle Announces First Wave of 2017 Speakers (PR Newswire)
08.08.17	DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
08.08.17	ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan (PR Newswire)
07.08.17	Drug Makers Stock Performance Review -- DURECT, Sucampo Pharma, Apricus Biosciences, and MEI Pharma (PR Newswire)
01.08.17	DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference Call (PR Newswire)
28.06.17	Daily Technical Summary Reports on Drug Makers Stocks -- Apricus Biosciences, DURECT, Sucampo Pharma, and SciClone Pharma (PR Newswire)
22.06.17	DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR® (PR Newswire)
19.06.17	DURECT's Collaboration with Sandoz Clears HSR Review and is Effective (PR Newswire)
10.05.17	DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
09.05.17	Gainers & Losers Of May 8: DRRX, CXRX, URGN, ARLX, TXMD... (RTTNews)
08.05.17	DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States (PR Newswire)
04.05.17	DURECT Corporation Invites You to Join its First Quarter 2017 Earnings Conference Call (PR Newswire)
24.04.17	DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017 (PR Newswire)
04.04.17	Pareteum Strengthens Sales Organization with Industry Veteran to Lead and Grow Worldwide Sales (PR Newswire)
03.04.17	DURECT to Present at the H.C. Wainwright NASH Investor Conference (PR Newswire)
20.03.17	How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma (PR Newswire)
14.03.17	DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs (PR Newswire)
24.02.17	DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call (PR Newswire)
31.01.17	Drug Makers Stocks on Investors' Radar -- Depomed, United Therapeutics, DURECT, and Orexigen Therapeutics (PR Newswire)
31.01.17	AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch (RTTNews)
30.01.17	DURECT Corporation Announces Update on DUR-928 Development Program (PR Newswire)
21.12.16	Research Reports Coverage on Drug Makers Stocks -- Depomed, DURECT, United Therapeutics, and Amphastar Pharma (PR Newswire)
27.09.16	ARRY Hits COLUMBUS Goals, KITE Flies After-hrs, FDA Places Hold On CVM Trial (RTTNews)
26.09.16	Pain Therapeutics Gets CRL From FDA For REMOXY ER Extended-Release Capsules CII (RTTNews)
26.09.16	FDA Approves AMGN's 1st Biosimilar, MRNS On Track, All Ears For DRRX, PTIE (RTTNews)
30.08.16	Biotech Stocks Facing FDA Decision In September (RTTNews)
02.08.16	SMA Data Endears IONS To Investors, PFE Opens Wallet, Busy Months Ahead For DRRX (RTTNews)
04.07.16	BIND Gallups On Stalking Horse Offer, KBIO Is Back, ALNY Abuzz (RTTNews)
27.04.16	DRRX Prices Offering At $1.25/Share (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Durect

Aktien Top/Flop

Meistgelesene Nachrichten